Volpara partners with US company on testing

Latest News

Medical technology company Volpara Health Technologies (ASX:VHT) has partnered with Ambry Genetics, one of the world’s leading genetic testing companies, to bring breast care to patients in the US.

Ambry Genetics, part of Konica Minolta Precision Medicine, is a leading clinical genetic testing company that has developed the CARE program. The CARE Program is a precision medicine platform designed to help ensure more patients get access to care.

Volpara said it will automate parts of the workflow to make it easier for women to get additional screening and testing. It said at least one Volpara software product is used in over 27 per cent of women who attend screening each year in the US.

"Customers utilize VolparaDensity for automated breast density assessment, an important breast cancer risk factor, along with breast cancer risk assessment modules in Aspen Breast (acquired from MRS Systems, Inc. in June 2019)," it said.

The company said its software products help providers make informed decisions about triaging patients to supplemental imaging and/or genetic testing based on risk. Risk assessment is also required by insurance companies to justify reimbursement for additional testing.

“Personalization of breast cancer screening based on risk is being adopted at a fast pace in the US, and Volpara is proud to be playing a major role in that. Our partnership with Ambry will allow us to offer additional value to our customers to ensure the right patients get the right testing at the right time,” said Volpara CEO Dr Ralph Highnam.

“With extra value from our platform, we expect to see a further increase in ARPU that we can achieve at each site.”

According to Tom Schoenherr, the chief commercial officer of Ambry Genetics, “We are excited about this partnership opportunity and the ability to help give providers confidence and peace-of-mind in elevating the standard of care for their patients.”